We have previously shown that a 20 amino acid peptide derived from the third ankyrin-like repeat of the p16 CDKN2/INK4a (p16) tumour suppressor protein (residues 84 ± 103 of the human p16 protein) can bind to cdk4 and cdk6 and inhibit cdk4-cyclin D1 kinase activity in vitro as well as block cell cycle progression through G1. Substitution of two valine residues corresponding to amino acids 95 and 96 (V95A and V96A) of the p16 peptide reduces the binding to cdk4 and cdk6 and increases its IC 0.5 for kinase inhibition approximately threefold when linked to the Antennapedia homeodomain carrier sequence. The same mutations increase the IC 0.5 approximately ®vefold in the p16 protein. Substitution of aspartic acid 92 by alanine instead increases the binding of the peptide to cdk4 and cdk6 and the kinase inhibitory activity. The p16 peptide blocks S-phase entry in nonsynchronized human HaCaT cells by approximately 90% at a 24 mM concentration. The V95A and V96A double substitution minimizes the cell cycle inhibitory capacity of the peptide whereas the D92A substitution increases its capacity to block cell cycle progression. A deletion series of the p16 derived peptide shows that a 10 residue peptide still retains cdk4-cyclin D1 kinase and cell cycle inhibitory activity. The p16 peptide inhibited S-phase entry in ®ve cell lines tested, varying between 47 ± 75%, but had only a limited (11%) inhibitory eect in the pRb negative Saos-2 cells at a concentration of 24 mM. Like the full length p16 protein, the p16 peptide does not inhibit cyclin E dependent cdk2 kinase activity in vitro. These data suggest that acute inhibition of CDKcyclin D activity by a peptide derived from the INK4 family will stop cells in late G1 in a pRb dependent fashion.
Introduction
The D type cyclins form kinase active complexes with the cyclin dependent kinases (CDKs) cdk4 (Matsushime et al., 1992) and cdk6 (Meyerson et al., 1994) and play a major part in phosphorylation and inactivation of the retinoblastoma protein (pRb) (Hinds et al., 1992; Ewen et al., 1993; Sherr, 1993; Kato et al., 1993; Weinberg, 1995) . pRb phosphorylation takes place at a time point in the later part of the G1 phase that coincides with the restriction point of the cell cycle in which the cells commit themselves to replicate DNA (Pardee, 1989; Geng and Weinberg, 1993) . The mitogen induced phosphorylation of pRb by CDK-cyclin D kinases releases the E2F transcription factor from pRb which leads to the induction of gene products that are essential for the cells to commence DNA replication (Bandara and La Thangue, 1991; Chellappan et al., 1991; Neveins, 1992; La Thangue, 1994) . The release of E2F also ensures that pRb remains in a hyperphosphorylated state by a feed back induction of cyclin E expression which together with cdk2 keeps pRb inactive in an mitogen independent fashion (Weinberg, 1995; Sherr, 1996) . In addition to the regulation of RNA polymerase II through E2F, pRb also suppresses activity of the RNA polymerases I and III which might contribute to its control of the cell cycle (White et al., 1996) . The CDK-cyclin D complex is further regulated by dierent phosphorylation events and by kinase inhibitory proteins of the p16
INK4a/CDKN2 and the p21 WAF1/KIP families (Hunter and Pines, 1994; Morgan, 1995; Sherr and Roberts, 1995) .
The importance of regulating the pRb phosphorylation pathway in G1 for controlled cell growth is emphasized by the frequency in which alterations of this pathway are detected in human cancers. Gene ampli®cation and chromosome rearrangement of regions in chromosome 11q13 that involve the cyclin D1 gene locus (also described as PRAD1 or bcl1), or overexpression of cyclin D1, are common events in various tumours including those of head and neck, oesophagus, bladder, breast and B-cell origin (Lammie et al., 1991; Hall and Peters, 1996) . The importance of cyclin D1 in the development of neoplastic growth is also stressed by the induction of hyperproliferative growth and carcinomas in mice carrying a transgenic cyclin D1 (Wang et al., 1994) . Cyclin D2 (Vin-1) has also been reported to be associated with oncogenic activities but at a much lower frequency (Tremblay et al., 1992; Hanna et al., 1993) .
Cdk4 is overexpressed in a subset of glioblastomas and sarcomas (Kathib et al., 1993; Schmidt et al., 1994; Reifenberger et al., 1996) and a mutation in cdk4 that impairs p16 binding and thereby prevents p16 from inhibiting cdk4-cyclin D1 kinase activity in vitro has been reported (WoÈ lfel et al., 1995) . Together with mutations in the Rb gene and loss of p16 function, alterations in genes regulating the pRb pathway have been reported in more than 90% of glioblastomas (Ischimura et al., 1996) .
Mutations of p16 are detected in approximately half of the tumours derived from oesophagus and the bilary tract and loss of p16 function through homozygous deletions are seen at similar frequency in glioblastomas, nasopharyngeal carcinomas, bladder cancer and acute lymphatic leukaemias whereas certain tumours, like pancreatic cancers frequently carry both types of mutations (Hall and Peters, 1996; Nobori et al., 1994; Kamb et al., 1994; Caldas et al., 1994; Herbert et al., 1994; Einhorn et al., 1994; Hirama and Koeer, 1995) . Silencing of p16 function through methylation of the promoter region has been reported in renal and lung cancers (Herman et al., 1994; Otterson, 1995) . Taken together, loss of p16 function is next to inactivation of p53 one of the most frequent events observed in human tumours. Evidence of p16s role as a tumour suppressor protein also comes from observations that families carrying p16 mutations are predisposed for malignant melanomas (Hussusain et al., 1994; Ranade et al., 1995) and that mice lacking p16 develop tumours early . P16 INK4a/CDKN2A (Serrano et al., 1994) and its closely related INK4/CDKN2 family members p15
INK4b (p15) (Hannon and Beach, 1994), p18 INK4c (p18) (Guan et al., 1994; Hirai et al., 1995) and p19
INK4d (p19) (Hirai et al., 1995; Chan et al., 1995) interact speci®cally with cdk4 and cdk6 and prevent the phosphorylation of pRb by the cyclin D-CDK complex in vitro. However, only p16 is strongly linked to tumour suppression activity. The exact mechanism of CDKcyclin D inhibition by the INK4 proteins and how this eects the CDK-cyclin D interaction remains to be elucidated. Dierent reports suggest that binding of p16 to cdk4 will block cyclin D interaction whereas others describe p16 and p19 in a complex together with both CDKs and cyclin Ds Hirai et al., 1995) .
Recent results might shed some light on potential physiological processes that requires p16 function in order to give it tumour suppressor function. The very low turnover of p16 mRNA and the observations of high levels of p16 in late passage number ®broblasts and keratinocytes are both in line with the idea that once p16 expression is induced it will lead to an irreversible exit from the cell cycle as part of the senescence mechanism Loughran et al., 1996; Alcorta et al., 1996) . This hypothesis is supported by data suggesting the existence of a gene involved in senescence mapping to the 9p21 locus (Loughran et al., 1994) and the loss of senescence in p16 7/7 mouse embryo ®broblasts .
In this report we have analysed the kinase inhibitory domain of human p16 and the closely related human p18 and mouse p16 (Quelle et al., 1996) in vitro. We have minimized the size of the p16 kinase inhibitory peptide and investigated its capacity to mimic p16 induced cell cycle arrest in the G1 phase of the cell cycle (Lukas et al., 1995; Serrano et al., 1995) in order to explore its potential as a lead molecule for anti proliferative therapeutics targeting cdk4 and cdk6 kinase activity. These results strengthen our previous ®ndings that a small peptide derived from the kinase inhibitory domain of the INK4 proteins can be used to block cells from entering the S-phase of the cell cycle and support the use of a small INK4 derived molecule as a CDK-cyclin D kinase inhibitor for anti proliferative purposes.
Results
A p16 derived peptide inhibits cdk4-cyclin D1 but not cdk2-cyclin E kinase activity
Our previous results have shown that a 20 aa synthetic peptide based on a sequence from the third ankyrinlike repeat of p16, corresponding to aa 84 ± 103 of the full length human p16 (p16) protein, has similar features as the full length protein including binding to the cyclin-dependent kinases cdk4 and ckd6, inhibiting cdk4-cyclin D1 kinase activity in vitro and block cells from entering the S-phase of the cell cycle. p21 WAF1/CIP1 (p21) inhibits cdk2, cdk4 and cdk6 derived kinase activity by direct interactions with both the cyclin and the kinase components of the enzyme complexes (Sherr and Roberts, 1995; Lin et al., 1996) and we have previously identi®ed a 20 aa peptide from the C-terminal domain of p21 that inhibits both cdk4 and cdk2 kinase activity in vitro (Ball et al., 1997) . In order to test the speci®city of the p16 peptide we compared the kinase inhibitory capacity of 25 mM of the p16 and the p21 peptides using Sf9 insect cell lysates coexpressing either cdk4-cyclin D1 or cdk2-cyclin E. As shown in Figure 1 , the p16 peptide and the p21 derived peptide blocks cdk4-cyclin D1 activity, but only the p21 derived peptide signi®cantly inhibits cdk2-cyclin E activity at this concentration. These results strengthen the speci®city of the p16 peptide in that it mimics the activity of the full length p16 protein by inducing a G1 arrest through inhibition of cyclin Ddependent kinase activity.
Characterization of the kinase inhibitory INK4 sequence
Members of the INK4 (CDKN2) family of kinase inhibitors block CDK-cyclin D kinase activity in a similar fashion through direct interaction with cdk4 and cdk6. The p18 (Guan et al., 1994; Hirai et al., 1995) and mouse p16 (Quelle et al., 1995) sequences are similar (60 and 90% identity, respectively) to the region of p16 corresponding to aa 84 ± 103 of p16 (Figure 2d ). Biotin-linked peptides from the same region of p18 and Figure 1 The p16
INK4a and the p21 WAF1/CIP1 derived peptides were incubated at 25 mM concentration with Sf9 cell lysates coexpressing either cdk4-cyclin D1 or cdk2-cyclin E. The kinase activity was determined using recombinant pRb as substrate. The values were obtained by densitometer analysis of the pRb band on the autoradiographs and the ®gure represents one of two similar experiments mouse p16 were synthesized and tested for binding to cdk4 and cdk6 and for inhibition of CDK-cyclin D kinase activity in order to understand more about which residues of the the INK derived peptides that are important for the inhibition of cdk4 and cdk6 kinases. Figure 2 shows that the p16 peptide (peptide 4) and peptides derived from the corresponding regions of the p18 and mouse p16 proteins (peptides 1 and 2) bind to in vitro translated cdk4 ( Figure 2a ) and cdk6 ( Figure  2b ) and inhibit cdk4-cyclin D1 phosphorylation of recombinant full length pRb protein in a similar manner (compare ®gures 2a, 2b and 2c).
Next we tested if the 20 aa p16 peptide could be minimized while still retaining kinase inhibitory activity. A p16 peptide deletion series was made by deleting residues from either the N-or the C-terminus ( Figure 2d) . Surprisingly, we found that deletion of two residues at either the C-terminus (peptide 5) or the N-terminus (peptide 7) severely reduced both the CDK binding and the kinase inhibitory capacity of the peptide and that the kinase inhibitory activity was restored when two more residues were deleted from either terminus (compare peptides 5, 6, 7 and 8 in Figure 2 ). Peptide 11 contains 10 residues that lie within a region that a previous alanine scan (FaÊ hraeus et al., 1996) identi®ed as important for both CDK binding and kinase inhibition. Since binding of peptides 5, 6, 7 and 11 to cdk4 and cdk6 is similar but 5 and 7 are not kinase inhibitory, it can be speculated that deletion of either the two N-or Cterminal residues (peptide 5 and 7) induces an infavourable conformation that inhibits these peptides Figure 2 Comparison of cdk4 and cdk6 interaction and cdk4-cyclin D1 kinase inhibition of INK4 derived peptides. Biotinylated peptides (see Materials and methods) derived from the human p16 (hp16) kinase inhibitory domain or from the corresponding domain of mouse p16 (mp16) or human p18 (p18) were analysed for binding to in vitro translated cdk4 (a) and cdk6 (b). Peptides bound to streptavidin coated agarose beads were used to precipitate 35 S-methionine-labelled cdk4 and cdk6. The relative binding was quanti®ed using densitometer analysis of the autoradiography. The same peptides were tested for their capacity to inhibit cdk4-cyclin D1 phosphorylation of recombinant pRb protein at 25 mM concentration (c). The dierent values in a, b and c represent one of at least two independent experiments and are given in relation to the data obtained with the human p16 derived peptide. (d) Dierences in the peptide sequences of human p18, mouse p16 and the R87P mutant compared to the human (hp16) sequence is underlined. This region corresponds to residues 84-103 of the p16 full length protein from interacting with the CDKs whereas peptides 6 and 11 interaction with cdk4 is sucient for inhibition of kinase activity but not for precipitating the kinases in the assay conditions used.
The R87P mutation is derived from a familial melanoma and it is inactive as a kinase inhibitor (Koh et al., 1995; Parry et al., 1996) . Residue 87 is located outside the 10 amino acid minimal CDK interacting domain and R87P has no eect on the kinase inhibitory capacity when inserted in the 20 residue peptide (peptide 3).
Eect of alanine substitutions at position 95, 96 and 92
Previous results have suggested that the two valines at position 95 and 96 are important for the binding of the p16 peptide to cdk4 and cdk6 and for its CDK-cyclin D1 kinase inhibitory function and that substitution of aspartic acid 92 to alanine increases both the binding to CDK and its kinase inhibitory activity (FaÊ hraeus et al., 1996) . These residues lie within the 10 amino acid minimal inhibitory region of the p16 peptide that is shown in Figure 2 . V95A and V96A double substitution and a D92A substitution were introduced into highly puri®ed p16 peptides linked to a 16 amino acid sequence derived from the third domain of the Antennapedia homeodomain allowing the peptides to be transported into cells directly from the tissue culture medium (Derossi et al., 1994) . This allows comparison of in vitro activity with cell cycle inhibitory capacity using the same peptides (see further in next section). We also introduced the V95A and V96A mutation into the full length His-tagged p16 protein in order to compare the eect of these amino acid substitutions in p16 full length protein and in the peptide with regard to kinase inhibition in vitro. Figure 3a shows that the IC 0.5 of the carrier linked p16 peptide with the V95A and V96A mutations increased the IC 0.5 approximately threefold (1.5 ± 4.5 mM) whereas the same substitutions in the His-tagged p16 protein increased the IC 0.5 less than ®vefold (6 ± 25 nM) of (Figure 3b ). It should be noticed that the IC 0.5 of the full length protein is signi®cantly lower than the IC 0.5 of the carrier linked p16 peptide and, interestingly, the IC 0.5 of a non-carrier linked p16 peptide is more than tenfold higher than of the carrier linked peptide (data not shown).
Cell cycle arrest by p16 derived peptides
The Antennapedia homeodomain sequence linked to the p16 peptide allows the chimeric peptides to be transported across the cell membranes directly from the tissue culture medium to both the cytoplasm and the nuclear compartments (Derossi et al., 1994) . In Figure 4 , biotinylated carrier-linked p16 peptides (pep 20 carries D92A substitution and pep 21 carries V95A and V96A substitutions) were added to the tissue culture medium 15 min and 2 h prior to ®xation and staining with FITC conjugated streptavidin. These results show that both peptides are delivered into the cells and distributed in the nucleus in a similar way, suggesting that any dierences in cell behaviour after adding these peptides are not likely due to dierences in peptide uptake.
In order to compare peptides 20 and 21 with thè wild type' carrier linked p16 peptide in terms of their ability to block cell cycle progression we added them directly to tissue culture medium containing 10% FCS using non-synchronized HaCaT cells or HaCaT cells that had been deprived of serum for 72 h. Cell cycle distribution was determined 24 h after peptide addition by studying BrdU incorporation by FACS analysis. Figure 5 shows that 12 mM of the p16 carrier linked peptide eciently blocks serum deprived HaCaT cells from entering S-phase after these cells have been treated with 10% FCS. The V95A and V96A double substitution has only a marginal eect on the cell cycle progression compared to the non-peptide treated cells, whereas the same concentration of the peptide carrying the D92A substitution induces a near complete G1 block. Table 1 shows a dose dependent inhibition of cells entering S-phase in the presence of p16 carrier linked peptides and that the concentration of peptides required to induce an equivalent G1 block in cells that have been serum deprived is approximately 50% less than for non-synchronized cells. The reason for this is not clear but it suggests that the amount of the protein/s that is target by the p16 peptide and/or the binding of the peptide to its target is reduced after serum deprivation. The data also shows that the V95A and V96A substitutions gives a slight inhibition of cell cycle progression which is in line with the eect of this peptide on cdk4-cyclin D1 activity in vitro (Figure 3b ). Table 2 shows that the maximal eect on cell cycle inhibition in HaCaT cell is obtained after 36 ± 48 h if the peptide is left in the medium. The decrease of cells in G1 after 36 ± 48 h suggests that the aect of the peptide is reversible, presumably due to degradation, or that a small population of cells is left unaected. The time course on serum deprived cells shows a similar pattern even though it has to be considered that BrdU uptake cannot be estimated until 24 h after serum addition and that the number of cells in G1 in the nontreated cells is increased after 36 h due to colony density. These results also show that the p16 peptide has little or no eect on the G2/M transition of the cell cycle.
We also compared the eect of the carrier linked p16 peptides on six dierent cell lines at approximately 50% con¯uence using 20 mM peptide concentration. Table 3 shows that the p16 peptide blocks S-phase entry in four of these cell lines in a fashion similar to that observed in the HaCaT cells, varying between 47 ± 75%. We also tested the pRb negative cell line Saos-2 and could show that the peptide only reduced the percentage of cells in S-phase from 36 to 32%, or reduced the entry of S-phase by 11%. Since p16 The Antennapedia carrier-linked p16 peptide was added to normal cycling HaCaT cells at 20 mM in the presence of 10% FCS 24 h before harvest. 72 h serum deprived HaCaT cells were treated with 10% FCS and 8 mM peptides 24 h before harvest. % cell cycle distribution was determined by FACS analysis induced cell cycle arrest has been shown to depend on the presence of a functional pRb protein (Lukas et al., 1995) these data strengthens the speci®city of the peptide.
The in vitro data demonstrate that the kinase inhibitory p16 derived sequence can be reduced to 10 amino acids. We also wanted to know if this sequence would be sucient to mediate cell cycle arrest. Two chimeric peptides were synthesized linking the Antennapedia carrier sequence to 14 and 10 residues of the p16 kinase inhibitory sequence and the cell cycle inhibitory capacity was compared with that of the p16 peptide carrying the D92A substitution (Table 4) . At 12 mM concentration these truncated peptides were as eective in blocking S-phase entry of serum deprived HaCaT cells as the longer peptide, demonstrating that a 10 amino acid peptide sequence linked to the carrier peptide is sucient to block cell cycle progression.
Discussion
There is mounting genetic data supporting the importance of controlled CDK-cyclin D kinase activity for normal cell growth. Deregulated expression of cyclin D1 and cdk4 are frequently seen in various human tumours and loss of p16 function is one of the most common events associated with human cancers (Sherr, 1996; Hall and Peters, 1996; Ichimura et al., 1996; Hirama and Koeer, 1995) . This work has focused on characterization of the kinase inhibitory domain of the INK4 family as a model for the development of small molecules in order to inhibit CDK-cyclin D activity in tumour cells that are defective in the regulation of the G1 checkpoint but carry a functional pRb.
Single amino acid substitutions that results in loss of function can be found throughout p16 (Ranade et al., 1995; Koh et al., 1995; Parry and Peters, 1996) . These mutations are often located outside the sequence of the p16 protein that is included in the minimal kinase inhibitory p16 peptide (residues 89 ± 98). We have previously suggested that these mutations would induce conformational changes in the protein that would eect the presentation of the kinase inhibitory domain of the p16 protein. Recent results obtained by NMR support this hypothesis since two mutations associated with familial melanomas, P114L and G101W, were both shown to induce global conformational changes of the p16 protein (Tevelev et al., 1996) . This is further supported by data demonstrating that the G101W mutation and another mutation associated with familial melanoma, V126D, are both temperature sensitive . The R87P mutation is, however, an inactive mutation that is not temperature sensitive and the R87P substitution peptide was synthesized in order to see if it would eect the kinase inhibitory activity of the peptide. We found that it did not eect either kinase inhibition or cdk4 and cdk6 binding of and since the R87 residue is not located in the minimal sequence required for direct interaction with cdk4 and cdk6 it is likely that the R87 mutation will only aect the kinase inhibitory domain when introduced in the full length protein.
The results obtained with the carrier linked p16 peptides show that alanine substitution for the two valine residues at positions corresponding to residues 95 and 96 of the full length protein increase the IC 0.5 of the CDK-cyclin inhibition in vitro approximately threefold in the p16 peptide linked to the Antennapedia carrier sequence and approximately ®vefold in the full length protein. These data indicate that the V95A and V96A substitutions have a similar eect on cdk4-cyclin D1 kinase inhibition in both the carrier linked peptide and in the full length protein. In this context it is also interesting to note that the carrier linked peptides has gained approximately tenfold higher activity in vitro compared to the non-carrier linked peptide suggesting that the carrier sequence confers stability to the p16 inhibitory peptide conformation.
Importantly, the carrier-linked peptide containing the V95A and V96A substitutions is less active as a cell cycle inhibitor compared to the wild type p16 peptide and the D92A substitution peptide is a more potent inhibitor. This suggests a strong correlation between the kinase inhibition in vitro and cell cycle inhibition.
In order to evaluate the possibility of using the p16 peptide as a lead for anti proliferative drug development we wanted to see if we could reduce the size of the p16 peptide from the original 20 residues to a size that could be possible to mimic with a small molecule. The deletion series presented in Figure 2 shows that the minimal sequence of the peptide can be reduced by at Non-synchronized cells were treated with 20 mM of p16 peptide linked to the Antennapedia carrier sequence for 24 h before being harvested and analysed by FACS. The percentage of cells in each stage of the cell cycle is given with or without peptide treatment Serum deprived HaCaT cells were treated with 12 mM of p16 derived peptides linked to the Antennapedia carrier sequence at the C-terminus. Cell cycle distribution was determined by FACS analysis 24 h after addition of 10% FCS and peptides least 10 residues without loosing activity. The 10 amino acid sequence (peptide 11) has lost its capacity to form a stable complex to cdk4 but is still eective as a kinase inhibitor and, most importantly, when linked to the Antennapedia carrier sequence this chimeric peptide blocks cell cycle progression. This deletion series, as well as a previous alanine scan of the p16 peptide, fails to identify peptides where there is clear binding to the CDKs but no kinase inhibition and, apart from the shorter peptides 6 and 11, there is a strong correlation between CDK binding and kinase inhibition.
The sequence of the 10 aa minimal inhibitory p16 peptide show similarities with the consensus of central ankyrin repeat which has been suggested to form an amphipatic helical wheel (Bork, 1993) . The p18 peptide carries eight substitutions of which three are located in the 10 aa minimal binding sequence compared to the p16 peptide. Since we previously identi®ed the hydrophobic residues 94 ± 97 as important for the p16 peptide function the glutamine at positions 95 and the threonine at position 96 in p18 would at ®rst seem to disrupt the consensus pattern of the binding domain. However, the p18 peptide carries two hydrophobic leucine residues at position 97 and 98 which allows it to form an amphipatic structure in the same helical wheel. Both the p16 and the p18 peptides have the GFLDTL sequence intact suggesting that this motif has an important role for the peptide interaction with cdk4 and cdk6.
The deletion series shows that when two residues are deleted from the N-or the C-terminal part of the peptide it loses its CDK binding and its kinase inhibitory activity and interestingly, both these properties are restored when two more residues are deleted from either end. This demonstrates that the conformation of the domain of the peptide that interacts with cdk4 and cdk6 can be, like in the full length protein, altered by residues located outside those directly involved in binding.
The p16 peptide has only marginal eect on blocking cell cycle progression through G1 in the pRb negative cell line Saos-2 suggesting that the cell cycle block depends largely on an intact pRb function which is in line with what would be predicted by a p16 mimicking CDK-cyclin D speci®c inhibitor (Lukas et al., 1995) . The in vitro results showing that the p16 peptide does not inhibit cdk2-cyclin E activity further indicate that the eect of the peptide is linked to the cyclin D dependent kinase activity at the G1 phase of the cell cycle.
The biochemical properties of p16 suggest that it mediates its tumour suppressor function by controlling CDK-cyclin D activity at the time of the restriction point in the late part of G1. It is, however, unclear why p16 and not its closely related INK4 family members are associated with tumour suppressor activity since the dierent INK4 proteins are thought to carry out similar CDK-cyclin D inhibitory function. This lack of redundancy might be due to post-translation modifications of the INK4 proteins that allows a higher degree of speci®city in the cells that is not observed in in vitro assays. In addition, the regulatory mechanism that distinguishes p16 function from the other INK4 proteins could be at the level of gene expression. Dierent signalling pathways have been suggested to control the levels of INK4a proteins in the cells. p15 expression is induced after the cells have been treated with TGF-b (Hannon and Beach 1995) and increased levels of p16 and p18 are observed in cells of late passage numbers (Hara et al., 1996; Alcorta et al., 1996; Loughran et al., 1996) and in skeletal muscle cells undergoing dierentiation (Franklin and Xiong, 1996) , respectively. This might suggest that in spite of similar biochemical activity, it is possible that the eect of CDK inhibition in the cell by the INK proteins can vary depending on the cell phenotype. This would imply that acute inhibition of CDK-cyclin D kinase activity by substances introduced directly into the cells, like the carrier linked INK4 peptides, will induce a G1 arrest which would be associated with dierent cellular events depending on cell phenotype and growth conditions.
The data presented here extend our previous observation that a small peptide that blocks cdk4-cyclin D1 kinase activity in vitro can be used to mimic the tumour suppressing function of the p16 protein.
The peptide, like the p16 protein, can inhibit cyclin D1 interaction with cdk4 if added to cdk4 prior to cyclin D1 FaÊ hraeus et al., 1996) , suggesting that a possible mean of action is to antagonize the formation of the holoenzyme complex. However, the p16 peptide, as well as the full length p16 protein, inhibits CDK-cyclin D1 activity when added to enzyme complexes that have already been formed without dissociating cdk4-cyclin D1, demonstrating that more work is needed in order to determine the mechanism/s of action of the p16 peptide as well as of the p16 protein.
Materials and methods

Peptides
Peptides were synthesized by Chiron Mimotopes and by Dr Weng Chan at the Department of Pharmacological Sciences at the University of Nottingham. The peptides used for the cdk4 and cdk6 precipitation and for in vitro kinase inhibitory assays carry a biotin group on a SGSG linker at the N-terminus of the peptide. The Antennapedia carrier sequence consists of 16 amino acids and was synthesized as a fusion peptide linked to the C-terminus of the p16 peptides.
Peptide precipitation
Peptide precipitation assays were carried out essentially as described previously (FaÊ hraeus et al., 1996; Ball et al., 1997) by coupling the biotinylated peptides to streptavidin coated agarose beads for 1 h at room temperature. After extensive washing the peptide-coupled beads were incubated with 3 ml of reticulocyte lysates containing either 35 Smethionine-labelled cdk4 or cdk6 in a total volume of 20 ml of PBS and protease inhibitors at 48C for 1 h. The beads were then washed with 1.56PBS containing 0.02% Triton X-100 before the samples were analysed by SDS ± PAGE followed by autoradiography. The bands were quanti®ed using a Bio-Imager densitometer analyser using whole band analyser software.
Kinase assays
Kinase activity was determined as described (FaÊ hraeus et al., 1996; Ball et al., 1997). Sf9 insect cells were infected with baculovirus constructs expressing cdk4 and cyclin D1.
Cells coexpressing cdk4 and cyclin D1 were lysed in 10 mM HEPES pH 7.4 buer containing 10 mM NaCl, 2 mM DTT, 1 mM EDTA and 0.1 mM PMSF. The kinase reaction was performed in a 15 ml 20 mM HEPES pH 7.5 containing 50 mM ATP (1000 c.p.m. pmol 71 [g 32 P]ATP), 10 mM MgCl 2 , 2.5 mM EGTA, 10 mM beta-glycerphosphate, 1 mM NaF, 1 mM DTT and 1 mM Benzamidine. The assays were started by addition of 0.3 mg of recombinant full length pRb and incubated for 10 min at 308C before the reaction was stopped by addition of SDS loading buer. The samples were then run on a SDS gel followed by a autoradiography and the bands were analysed using a BioImager densitometer. p16 p16 full length protein was obtained by expressing a pRSET His-tagged fusion construct (kindly provided by G Peters) in E. coli and the following puri®cations over a nickel chelating column according to the manufacturers manual (Invitrogen). The alanine substitutions were introduced by site directed mutagenesis (Promega) and the sequence was con®rmed by DNA sequence analysis.
Peptide uptake
Peptide uptake into the cells was determined by adding biotinylated Antennapedia carrier-linked human derived p16 peptides directly into the tissue culture medium. After 15 min and 2 h the cells were washed in medium and ®xed in ethanol : acetic acid (9 : 1) and blocked in medium containing 10% FCS and 0.02% Tween-20 before being incubated with FITC conjugated streptavidin. The cells were mounted in Mowiol containing Hoescht nuclear stain for viewing by confocal microscopy. Non-peptide treated cells did not stain using this protocol.
FACS analysis
HaCaT cells were either serum deprived for 72 h or cultured in 10% FCS before peptides and DMEM medium containing 10% FCS were added. Cells were incubated for 24 h in the presence of peptide before 10 mM BrdU was added for 20 min. Cells were harvested and ®xed in 75% ethanol before treatment with pepsin (1 mg/ml) for 30 min and 2 M HCl for 15 min. After extensive washings in PBS, anti-BrdU mAb was added for 1 h in room temperature before they were washed once and FITC conjugated secondary antibodies was added. The cells were ®nally resuspended in PBS containing propidium iodine and analysed by single cell¯ow cytometry.
Cell lines
Cells were cultured in DMEM with 10% FCS. HaCaT is a human derived keratinocyte line, MCF-7 is derived from a human breast carcinoma, MRC-5 cells are human ®broblasts, 3T3 cells are mouse ®broblast, HT-29 is a human colon carcinoma derived cell line and Saos-2 is an Rb negative human sarcoma derived cell line.
